Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2021-04-07 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
2020年度内部控制鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制鉴证报告' which translates to 'Internal Control Assurance Report'. It is issued by a certified public accounting firm and addresses the effectiveness of the company's internal controls related to financial reporting as of December 31, 2020. The document includes an internal control self-evaluation report by the company management and an auditor's assurance opinion on the internal control effectiveness. It references regulatory standards for internal control and describes the scope, methodology, and conclusions of the internal control evaluation. The document is not a full annual report or interim financial report but a standalone audit-related assurance report on internal controls. It does not contain full financial statements or comprehensive financial performance data but focuses on internal control effectiveness. This matches the definition of an Audit Report / Information (AR) filing, which includes standalone audit reports and results of internal control evaluations. The document length (6642 characters) and content confirm it is the report itself, not merely an announcement or certification letter. Therefore, the appropriate classification is AR with high confidence. FY 2020
2021-04-07 Chinese
监事会关于2020年度内部控制自我评价报告的核查意见
Regulatory Filings Classification · 95% confidence The document is a supervisory board's opinion on the company's 2020 internal control self-evaluation report. It references regulatory requirements and internal control systems but does not contain actual financial statements or detailed financial data. The document is short (455 characters) and appears to be an official statement or opinion rather than the full internal control report itself. It fits best as a Regulatory Filing (RNS) because it is a compliance-related announcement without substantive financial data or full report content.
2021-04-07 Chinese
国元证券关于公司2020年度持续督导跟踪报告
Regulatory Filings Classification · 95% confidence The document is titled as a "2020年度持续督导跟踪报告" which translates to "2020 Annual Continuous Supervision Follow-up Report" by the sponsoring institution Guoyuan Securities Co., Ltd. It details the supervision work overview, findings, company and shareholder commitments, and other matters related to the supervision of Anhui Anke Biotechnology (Group) Co., Ltd. The content focuses on the sponsor's review and monitoring activities rather than presenting full financial statements or comprehensive annual financial performance. The document length is relatively short (1939 characters), and it is a report on ongoing supervision rather than a full annual report or audit report. This type of document fits best under the category of Regulatory Filings (RNS) as it is a regulatory compliance and supervision report that does not fit into other specific categories like Annual Report (10-K) or Audit Report (AR).
2021-04-07 Chinese
关于向银行申请综合授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Anhui Anke Biotechnology (Group) Co., Ltd. regarding the company's application for a comprehensive credit line from banks. It details the board meeting resolution to apply for a credit limit of up to RMB 300 million, authorization for the chairman to sign related documents, and the need for shareholder approval. There is no financial report, earnings data, or detailed financial statements. The content focuses on financing activities and credit facilities. Therefore, this fits the category of Capital/Financing Update (CAP). The document length is short and it is not merely announcing a report publication, so it is not RPA or RNS.
2021-04-07 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change in accounting policy by Anhui Anke Biotechnology Engineering (Group) Co., Ltd. It details the reasons for the change, the new accounting standards being adopted, and the impact on the company. It includes approvals from the board of directors, supervisory board, and independent directors. The document is relatively short (2167 characters) and does not contain actual financial statements or detailed financial data. It is an announcement of a policy change rather than a full financial report or audit report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-04-07 Chinese
独立董事对相关事项的独立意见
Governance Information Classification · 95% confidence The document is an independent opinion statement from the independent directors of Anhui Anke Biotechnology (Group) Co., Ltd. regarding various company matters including the 2020 internal control self-assessment report, related party transactions, audit firm reappointment, profit distribution plan, executive compensation, cash management, related party transactions confirmation, and accounting policy changes. It references regulatory guidelines and provides detailed opinions on these governance and financial control issues. The document is not a full annual report or audit report but rather a formal independent directors' statement on governance and financial matters, which aligns with the nature of a Governance Information (CGR) filing. The document length is under 5,000 characters and contains substantive content rather than just an announcement or certification, so it is not RPA or RNS. Therefore, the best classification is Governance Information (CGR).
2021-04-07 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.